Equities

Magle Chemoswed Holding AB

Magle Chemoswed Holding AB

Actions
  • Price (SEK)31.00
  • Today's Change0.80 / 2.65%
  • Shares traded1.02k
  • 1 Year change+3.33%
  • Beta0.4037
Data delayed at least 15 minutes, as of Apr 19 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Magle Chemoswed Holding AB is a Sweden-based company that conducts research, development and manufacturing in the fields of pharmaceutical chemistry and pharmaceutical technology. The Company's operations are mainly conducted through the subsidiaries Magle Chemoswed AB and Adroit Science AB. The business is focused on process development and manufacturing of Active Pharmaceutical Ingredients (API) as well as research, development and manufacturing of products in the areas of wound care and diagnostics with particular focus on products based on degradables starch microspheres. Magle Chemoswed also functions as a consultancy in material characterization and solid phase analysis with a main focus on pharmaceutical companies.

  • Revenue in SEK (TTM)170.44m
  • Net income in SEK12.17m
  • Incorporated2012
  • Employees78.00
  • Location
    Magle Chemoswed Holding ABAgneslundsvagen 27MALMO 212 15SwedenSWE
  • Phone+46 40383300
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Exact Therapeutics AS0.00-35.75m223.01m8.00--4.67-----1.20-1.200.001.500.00-------49.19-33.93-57.46-38.22------------0.031------31.55------
Corline Biomedical AB25.03m-1.81m234.25m13.00--2.51--9.36-0.0841-0.08411.164.340.248--10.921,925,385.00-1.79-5.71-1.92-6.24113.38128.60-7.22-38.46---89.40----6.2874.14-177.67--62.51--
SynAct Pharma AB0.00-215.81m238.50m5.00--1.35-----6.54-6.540.004.950.00----0.00-116.46-125.17-130.53-151.70------------0.0036-------117.54------
Lipum AB (publ)0.00-37.18m244.04m----13.86-----4.05-4.050.000.47260.00-------159.35-127.85-206.31-184.50-------293,228.70----0.2781------2.38------
Thor Medical ASA0.00-5.52m247.23m1.00--0.9155-----0.0318-0.1520.001.160.00----0.00-2.52-79.17-2.84-113.94------------0.00--------------
Arctic Bioscience AS33.52m-45.20m250.68m20.00--0.9763--7.48-1.79-1.791.3310.190.10750.70252.931,687,501.00-14.50---16.61--28.96---134.86--2.53--0.0079---1.52---33.77------
Lumito AB (publ)0.00-25.80m272.50m15.00--2.64-----0.125-0.1250.000.49970.00----0.00-19.98-20.77-22.14-22.38--------1.42--0.0884------4.56------
Lytix Biopharma AS3.96m-87.33m276.26m----4.35--69.70-2.16-2.160.09811.260.037--0.4091---81.63-57.34-94.30-66.09-----2,203.36-4,665.04--------183.2563.94-57.01------
Hamlet BioPharma AB0.00-26.59m278.53m7.00--6.15-----0.207-0.2070.000.35430.00-------63.29-83.52-69.05-107.84------------0.0984-------18.87--78.01--
Ultimovacs ASA0.00-187.93m285.65m27.00--1.03-----5.50-5.500.008.120.00----0.00-44.08-28.80-50.02-31.12------------0.0131-------12.78---45.35--
Aqua Bio Technology ASA13.42m-1.49m288.55m2.00--13.51335.6721.50-0.1599-0.15990.49380.36730.30790.65489.01---3.42-80.72-6.75-125.2966.695.57-11.12-965.980.10440.6110.7538--349.8842.041.97------
Medivir AB7.63m-89.32m300.30m10.00--1.29--39.34-1.46-1.460.11272.090.0292--2.73763,300.00-34.22-28.91-41.03-34.77-802.20-467.42-1,170.21-675.96----0.0585--73.16-20.39-0.6275---47.96--
Intervacc AB8.02m-102.85m316.96m15.00--1.33--39.55-1.47-1.470.11673.140.03063.081.72534,333.30-39.21-17.62-42.12-18.77-628.60-243.59-1,283.24-626.904.38--0.0006---17.23-25.79-60.31---38.72--
Magle Chemoswed Holding AB170.44m12.17m326.16m78.0026.802.0612.901.911.131.1315.7814.650.64830.495510.282,185,128.004.632.526.013.5290.3185.677.143.920.64326.160.2760--17.009.9733.07---6.34--
Herantis Pharma Oyj0.003.27m341.26m10.00115.356.19104.46--0.01260.01260.000.23440.00----0.004.31-80.466.16-104.37------------0.0073------103.00------
INIFY Laboratories AB1.19m-53.33m411.78m----4.84--345.16-1.19-1.190.02661.89----------------71.50---4,470.08---------------20.76------
Data as of Apr 19 2024. Currency figures normalised to Magle Chemoswed Holding AB's reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.